The mechanism of immunotherapy agents currently used for numerous malignancies depends on reinstating the activity of immune cells, predominantly T-cells, against cancer cells by blocking inhibitory pathways, with programmed cell death-1 (PD-1)/PD-L1 axis being their most prominent target. The gene discussed is CD274; the disease is cancer.